The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs

Abstract

Background: We studied the clinical efficacy of the intensive phase of treatment of TB patients with bacterial excretion and presence of the lever diseases, depending on the way of administration of anti-TB drugs (ATD). Materials: 46 patients with newly diagnosed pulmonary TB with the bacterial excretion and confirmed liver diseases (toxic hepatitis, viral hepatitis C, etc.) with moderateandmarkedincreaseofALT were randomized into main and control groups: 23 patients of the main group received complex treatment with 60 doses of isoniazid intravenously (10% solution for infusion), rifamycin sodium salt (30 mg/ml concentrate for preparation of the solution for infusion) and ethambutol hydrochloride (10% solution for infusion) in doses permissible by Pharmacopeia together with oral pyrazinamide. 23 patients of the control group received a standardized oral chemotherapy. Results: The complex treatment regimens involving parenteral administration of ATD resulted in the reduction in the mean terms of sputum conversion to 0.5 months., increase of the tendency towards the healing cavities of destruction on 23% (64.6 ± 7.85) vs control (41.3 ± 7.85), (p> 0.05). Additionally, increased tolerability of the intensive phase of chemotherapy with parenteral administration was reported. Conclusions: Parenteral administration of ATD in the intensive phase of treatment in patients with pulmonary TB with liver diseases reduces the timing for the sputum conversion, increase the incidence of the healing of cavities of destruction, improves the tolerability of the chemotherapy and prevents treatment interraptions.